Similar articles for PMID: 29986989

Year	Number of Results
1992	1
1995	2
1996	1
2000	2
2001	1
2002	3
2003	2
2004	2
2005	1
2006	1
2010	1
2011	1
2012	2
2013	10
2014	10
2015	10
2016	34
2017	29
2018	25
2019	25
2020	14
2021	13
2022	14
2023	2
2024	0

1

Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors.

Shahreyar M, Salem SA, Nayyar M, George LK, Garg N, Koshy SKG. Shahreyar M, et al. J Am Board Fam Med. 2018 Jul-Aug;31(4):628-634. doi: 10.3122/jabfm.2018.04.170447. J Am Board Fam Med. 2018. PMID: 29986989 Free article. Review.

2

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.

Yadav K, Sharma M, Ferdinand KC. Yadav K, et al. Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30. Nutr Metab Cardiovasc Dis. 2016. PMID: 27352986 Review.

3

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview.

Noel ZR, Beavers CJ. Noel ZR, et al. Am J Med. 2017 Feb;130(2):229.e1-229.e4. doi: 10.1016/j.amjmed.2016.09.021. Epub 2016 Oct 15. Am J Med. 2017. PMID: 27751895 Review.

4

Lipid Lowering Therapy and Circulating PCSK9 Concentration.

Nozue T. Nozue T. J Atheroscler Thromb. 2017 Sep 1;24(9):895-907. doi: 10.5551/jat.RV17012. Epub 2017 Aug 14. J Atheroscler Thromb. 2017. PMID: 28804094 Free PMC article. Review.

5

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.

Blom DJ, Dent R, Castro RC, Toth PP. Blom DJ, et al. Vasc Health Risk Manag. 2016 May 9;12:185-97. doi: 10.2147/VHRM.S102564. eCollection 2016. Vasc Health Risk Manag. 2016. PMID: 27274264 Free PMC article. Review.

6

PCSK9 inhibition - a novel mechanism to treat lipid disorders?

Banach M, Rizzo M, Obradovic M, Montalto G, Rysz J, Mikhailidis DP, Isenovic ER. Banach M, et al. Curr Pharm Des. 2013;19(21):3869-77. doi: 10.2174/13816128113199990303. Curr Pharm Des. 2013. PMID: 23286435 Review.

7

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

Sahebkar A, Watts GF. Sahebkar A, et al. Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Clin Ther. 2013. PMID: 23932550 Review.

8

The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies.

Lambert G, Thedrez A, Croyal M, Ramin-Mangata S, Couret D, Diotel N, Nobécourt-Dupuy E, Krempf M, LeBail JC, Poirier B, Blankenstein J, Villard EF, Guillot E. Lambert G, et al. Clin Sci (Lond). 2017 Feb 1;131(4):261-268. doi: 10.1042/CS20160403. Clin Sci (Lond). 2017. PMID: 28108631 Review.

9

PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).

Watts GF, Chan DC, Pang J, Ma L, Ying Q, Aggarwal S, Marcovina SM, Barrett PHR. Watts GF, et al. Metabolism. 2020 Jun;107:154221. doi: 10.1016/j.metabol.2020.154221. Epub 2020 Mar 30. Metabolism. 2020. PMID: 32240727

10

What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?

Stein EA. Stein EA. Curr Opin Endocrinol Diabetes Obes. 2016 Apr;23(2):97-105. doi: 10.1097/MED.0000000000000242. Curr Opin Endocrinol Diabetes Obes. 2016. PMID: 26859553 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

179 results

Results by year